Cidara Therapeutics’ stock is on the rise due to positive developments in its CD388 Flu program. The company’s strategic advancements, particularly the expansion of the Phase 3 ANCHOR study, have broadened its market potential, prompting analysts to maintain Buy ratings. Although Cidara reported a net loss, its increased cash reserves bolster confidence in the continued development of CD388, which is expected to be a universal preventative for influenza.
https://www.tipranks.com/news/catalyst/cidara-therapeutics-stock-climbs-amid-flu-program-success
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.